{"name":"Allecra","slug":"allecra","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AAI101 i.v.","genericName":"AAI101 i.v.","slug":"aai101-i-v","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"cefepime/AAI101 combination","genericName":"cefepime/AAI101 combination","slug":"cefepime-aai101-combination","indication":"Complicated urinary tract infections","status":"phase_3"}]}],"pipeline":[{"name":"AAI101 i.v.","genericName":"AAI101 i.v.","slug":"aai101-i-v","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"cefepime/AAI101 combination","genericName":"cefepime/AAI101 combination","slug":"cefepime-aai101-combination","phase":"phase_3","mechanism":"Cefepime/AAI101 combination is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.","indications":["Complicated urinary tract infections","Nosocomial pneumonia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQUHBMNF80Q2ZiNFp2N193S2pBOWlfVlFTYmMwYlotT0RkdG9sWWtUYTREYVV2N1JCX2p4LW9iZWIteTltMnZoRUpreC1KeHI4V2IzQ3A1Z3JvVUNLdklRX3hXSzhyQ1ZRLVpWVmwwVjk5R3JtOHZ4Y1FiUDVrakZMRUM3OXlSRWlxeFdCTGdGYTNLRU5PTUxUcmtHY2ZWVjFVSFh4cFVXdXVuWVFsZjBHOG9acnctVFF2d2ZYWVpXcG9ndkYtWnJoUjh3NA?oc=5","date":"2025-10-30","type":"pipeline","source":"scanx.trade","summary":"Orchid Pharma Finalizes Acquisition of Allecra Therapeutics Assets - scanx.trade","headline":"Orchid Pharma Finalizes Acquisition of Allecra Therapeutics Assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-08-08","type":"pipeline","source":"Business Standard","summary":"Orchid Pharma gets formal nod from Court of France for Allecra Therapeutics acquisition - Business Standard","headline":"Orchid Pharma gets formal nod from Court of France for Allecra Therapeutics acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPSEtNV0t2MkNGNk9XcC1mY1dCTERIQW5Md1VwZXZOMUJlNmNxVHdDUlpSRENTNGRNcTVxQzAtTFpLdG5sQXRNRGJfeFViOTdpUUUtWFRWdlNzSXl6RV9qRXpvdmZqUVpsenVjbjBxUV9URFg0eUt2Z0xsV1ZqeWVWYWgyMktXZjVTTWszaW4zTmFWUjVNT3NIV3RVZDIxdTYyUnlzdlBMSnNPOU5iT29VMzZJbWZtX2hMUVlON0R5a2ltZ3dycjJaQTZRMHBOLWE4QWgxSzh1QWdJSTVOVFdZdWJQNFE4Zw?oc=5","date":"2025-08-05","type":"regulatory","source":"scanx.trade","summary":"Orchid Pharma Secures French Court Approval for Allecra Therapeutics Asset Acquisition - scanx.trade","headline":"Orchid Pharma Secures French Court Approval for Allecra Therapeutics Asset Acquisition","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNWnBHODRpS1J6QjlMb0Y5eU1veTB5YTliZWNDa1dPTmNfaEJNWlg4cWh5NGotMWZHa0VoYWpEYi1SX0dUQ3RwLXBmOFdKMG5jLU5IQXJhNlV3dV9jS2gzZENlakFOSkdfWDRnSXhGbDVEd05YMlQ3eVh1T1VqRnU2VWd4ZmhSZzBTNHpGR2ZZM1A5a01WNEw3WG1lQXI1UExEWFE?oc=5","date":"2025-07-31","type":"deal","source":"Equitypandit","summary":"Orchid Pharma Hits Upper Circuit on Buyback of Novel Antibiotic Rights - Equitypandit","headline":"Orchid Pharma Hits Upper Circuit on Buyback of Novel Antibiotic Rights","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-31","type":"regulatory","source":"Business Standard","summary":"Orchid Pharma hits 5% upper circuit in trade; why is the stock in demand? - Business Standard","headline":"Orchid Pharma hits 5% upper circuit in trade; why is the stock in demand?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxONDVnZEE1SUVTYWlhellXNi0yeHIwcHd6dkxXOEhjajBNZXpSVVRfSi1uRnp0OExtR3JPaFFmU0pudDNCU2JCb21kbUpYMTVUeGRNbC0xcHdZS0J6SjBOR0FzMzVqR1hTaDlsSEhlWFJWelJ1QVpRTkJ6YUV0MTFwQmh1MVdHYkJqZXkzV2h3emhERmVuWm1HUUpZR3hwamhCMEZNNzJJUHlmS2puWGZVLXM4NE1TdGtIR1JXWm1hb21tcURiRmlYcy1xZldPY2h0TEtuN0tnRk1YZHdQQnc?oc=5","date":"2025-07-30","type":"pipeline","source":"scanx.trade","summary":"Orchid Pharma Shares Surge as Company Reclaims Global Rights to Novel Antibiotic - scanx.trade","headline":"Orchid Pharma Shares Surge as Company Reclaims Global Rights to Novel Antibiotic","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-03-01","type":"regulatory","source":"Express Pharma","summary":"Allecra’s EXBLIFEP approval to treat cUTIs provides valuable new weapon to tackle ESBL mediated AMR: GlobalData - Express Pharma","headline":"Allecra’s EXBLIFEP approval to treat cUTIs provides valuable new weapon to tackle ESBL mediated AMR: GlobalData","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQTUw4MVBWUm5UTlRRY0ZKdk94MF9MVDVIZnFNT2EwMzU1QzdTNFFzdXBpRDNzNk5qcWY4MDlENTJ1NXI3N3YyR1JnWFVQYzgxTGR2ODFsODVkX0RCSUp0dGlaTURzcFB6dnE0QlNVUS1Uby1zSUNTYXNDZnk2aFpBMGktdw?oc=5","date":"2024-02-28","type":"regulatory","source":"Pharmaceutical Technology","summary":"US FDA approves Allecra's EXBLIFEP for cUTI treatment - Pharmaceutical Technology","headline":"US FDA approves Allecra's EXBLIFEP for cUTI treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOUEY3ZDBkUXZzazlOTUp6UTRIOEhFdHBGdktTSkxuZUZvaTNCSzlZZ1pxRVZ0cnlwazkzNmRNVVhqU01lZ0RuTjZXNkFiVmZaNk9iM1cwZVlveVpQUEg5OVdKMFZKZ2JIbDFXRHRxLXNXaUFBbFNncjl0eTR6N1ZTZXNZRFA1Yk9GbjNhMXIydm0zUmhabWhsY1RaLWRoMDZhUGpQenprZDctVnlrd3pxYQ?oc=5","date":"2024-02-27","type":"regulatory","source":"Fierce Pharma","summary":"One up, one down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection - Fierce Pharma","headline":"One up, one down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOcTFGVS05ZTRlWWc5LUU3U3RJTXVPQW5yYjNhSG9kMjhhT21qcjlkdnY0ZHlkTkRwWTVzWXFIak1PSFlVS3NPWDFjX0paMXRYYVFUSkNMbWpHdW1JWFljRnlDQWc4RXRmTXpEUlRDTkQtQmRWNm1DN3FXWjYxMEpEN0dSbUV1c2wtTHRfUVFnbHBTeG1Zb3IyR2lVX0k2SVM0RC1jbzIxZE5YQ245YlhUYlV2d3V5ZnRheUFLaWNYay1CZm1UOTVBWU9tai1YY1hudm5yVklDWjAzZ3NjOWEwcFJYSVBCSlNLWmg3cl9nT2p5bVM3RFNHeUhHaGo3Ynd5Rk5TT0N5RQ?oc=5","date":"2024-02-27","type":"regulatory","source":"Business Wire","summary":"Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections - Business Wire","headline":"Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1VUFVxQTVJd1AxcjZpN2lCUVdzY1pxaUZKQlRiRXNaZmd0a290bVJjNXY0T0U0emY4UXYzMG1wNTBBR0l5cDFwdHZrS3h2WVplczVydkZfUlBvYVNpSERCWXIwNVd3R05qT0dyT1F6eWZkV0R4MDFXOUlmc1E?oc=5","date":"2024-02-27","type":"regulatory","source":"pharmaphorum","summary":"FDA says yes to Allecra, no to Venatorx UTI drugs - pharmaphorum","headline":"FDA says yes to Allecra, no to Venatorx UTI drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNNWlMVUlXYkdiTVFjSGVmYmpoWThIN09WcFpNUXB3a3E1WVBMeU8tSHF6SUIzZXZsNnBYVWlYTmdnRzRlRXVyQk9BYVF4cG5QbnJONk9RR1Z2Y0IzZ3U2UnNnNXRIX1Z4LXhkVkJIRkpJMktTZmxFa3pDTVFnUnBoVWhlMWZoT2RDYl94b2RmR09XeVh0eklZM2F2REd5TmZDQ21ZQg?oc=5","date":"2017-04-07","type":"pipeline","source":"PMLiVE","summary":"Dr Engelbert Tjeenk Willink joins Allecra Therapeutics - PMLiVE","headline":"Dr Engelbert Tjeenk Willink joins Allecra Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}